Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review

Gregory Reardon 1
Sameer Kotak 2
Gail F Schwartz 3

1Informagenics, LLC, Worthington, OH, USA; The Ohio State University College of Pharmacy, Columbus, OH, USA; 2Pfizer Inc, New York, NY, USA; 3Glaucoma Consultants, Greater Baltimore Medical Center; Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA

Purpose: This study summarizes findings from objective assessments of compliance (or adherence) and persistence with ocular hypotensive agents in patients with glaucoma and ocular hypertension.

Design: Systematic literature review.

Methods: A PubMed and reference list search was conducted across publication years 1970–2010, using these terms and variants: “compliance,” the equivalent term “adherence,” and “persistence” in patients with these conditions and therapies. Summaries of selected studies were stratified by measurement method (electronic monitor, prescription fills review, medical chart review). Measures of central tendency across studies were calculated for commonly-reported compliance or persistence measures.

Results: Fifty-eight articles met all inclusion/exclusion criteria: measurement of compliance–electronic monitoring (seven studies reported in 14 articles), measurement of compliance/persistence–prescription records (36 studies in 38 articles), and measurement of persistence–medical chart review (six studies in six articles). From electronic monitoring, most therapy-experienced patients took medication consistently, but 20% met criteria for poor compliance. From prescription records, only 56% (range 37%–92%) of the days in the first therapy year could be dosed with the medication supply dispensed over this period. At 12 months from therapy start, only 31% (range 10%–68%) of new therapy users had not discontinued, and 40% (range 14%–67%) had not discontinued or changed the initial therapy. From medical chart review, only 67% (range 62%–78%) of patients remained persistent 12 months after starting therapy.

Conclusions: Evidence provided by this review suggests that poor compliance and persistence has been and remains a common problem for many glaucoma patients, and is especially problematic for patients new to therapy. The direction of empirical research should shift toward a greater emphasis on understanding of root causes and identification and testing of solutions for this problem.

Keywords: persistence, adherence, glaucoma, ocular hypertension, review

Introduction

As with many chronic insidious conditions, such as hypertension and diabetes, unsuccessfully controlled glaucoma typically worsens through a gradual progression, producing few symptoms until further permanent debilitation occurs, the latter condition being diagnosed in part upon the appearance of damage to the optic nerve (e.g., cupping or loss of visual field). Glaucoma may be preceded by the appearance of ocular hypotension, an asymptomatic condition marked by elevated intraocular pressure (IOP) which often, but not necessarily, progresses to glaucoma.
Without the reinforcing amelioration of symptoms through use of pharmacotherapy, patients with glaucoma and ocular hypertension may be less inclined to maintain regular and continued use of their ocular hypotensive therapy. The additional self-administration hurdle of topical eye drops (compared with the oral formulations commonly used in other conditions) may further depress the motivation of these patients to comply and persist with therapy.  

In a recent editorial, Quigley makes a case for why clinicians should seriously consider this problem: 

“If we could help patients with glaucoma take their drops better, it would be like doubling the effect of their treatment – the equivalent of adding a second drop. This is true because, on average, patients with chronic medical conditions take from 30% to 70% of prescribed medication doses, and up to half discontinue medications in the first months of therapy. These dismal facts apply to the use of eye medicines as well.”

Although one review found no strong evidence supporting an association between compliance and glaucoma progression, longitudinal research into this association remains quite limited. For ophthalmologists, the treatment goal remains: to provide patients with appropriate ocular hypotensives for their clinical and personal needs and to encourage compliance so that a desired level of IOP is reached.

Although one might consider compliance and persistence problems in glaucoma to be common knowledge, systematic reviews are useful for providing a more objective and thorough summary of the weight of evidence across the empirical knowledge base. In a 2005 systematic review devoted to glaucoma non-compliance, Olthoff et al reported that the proportion of patients who deviated from their prescribed medication regimen ranged from 5% to 80%. These authors further found that no determinants (patient factors) were sufficiently sensitive and specific to accurately identify potential non-compliers. In a recent systematic review of glaucoma therapy issues, which also included a section on compliance and persistence problems, Lu et al found that “[r]ates of nonadherence ranged between 23% and 60% over 12 months … [r]ates of non-persistence ranged between 30% and 95% at 1 year.”

Since the time of the focused review by Olthoff et al, the number of empirical publications on this topic has approximately doubled (based on the number of eligible studies identified in the current study). The purpose of the current study is to update these earlier reviews on the measured magnitude of compliance or persistence problems in glaucoma (but this time limiting the scope to objective assessments rather than addressing the problematic issues related to self-reported compliance assessment without objective reference), to stratify findings by measurement method used (ie, electronic monitor, prescription fills, and medical chart), since each captures a different aspect of compliance and persistence, and to summarize findings by central tendency rather than by all-encompassing, but perhaps less-useful general ranges of findings. Due to the large number of eligible studies identified in the current study, additional issues examined in earlier reviews regarding the association between choice of agent and associated levels of compliance or persistence, and the association of compliance and persistence with visual field loss are not examined, but are left for future focused evaluations.

**Methods**

**Terminology**

In a recent report, a health outcomes working group cited the lack of guidance regarding the terms “compliance,” “adherence,” and “persistence.” This group concluded that compliance and adherence are synonyms, compliance simply being the more commonly used term. Medication compliance (or its synonym adherence) is thus defined as “…the degree or extent of conformity to the recommendations about day-to-day treatment by the provider with respect to the timing, dosage, and frequency.” Medication persistence was further defined by this working group as “… the act of continuing the treatment for the prescribed duration. It may be defined as ‘the duration of time from initiation to discontinuation of therapy’.” Despite the finding of this working group for equivalence of the terms “compliance” and “adherence,” Osterberg and Blaschke state, that “[t]he word ‘adherence’ is preferred by many health care providers, because ‘compliance’ suggests that the patient is passively following the doctor’s orders and that the treatment plan is not based on a therapeutic alliance or contract established between the patient and the physician.” However, for purpose of this review, we avoid interpretation of authors’ intent in usage of these terms (which is often unclear) but rather favor the position of this working group to view the term “adherence” as neither less derogatory nor as more preferred by patients, but as simply synonymous with “compliance.” Thus, to provide a standardized terminology, in the body of this review we substitute the term “compliance” for those instances where
authors used the term “adherence.” However, to maintain a bridge of continuity with the original publication, in the summary tables describing each study we provide the exact terms as used by the original authors.

**Literature search and article selection**

A systematic literature review was conducted using the PubMed search tool to search MEDLINE and other life science journals (www.ncbi.nlm.nih.gov/pubmed). The following search terms, applied to the full PubMed database, were used: (compliance OR adherence OR adherent OR persistence OR persistency) AND (glaucoma OR ocular hypertension). English language studies published in journals over the time period 1/1/1970–12/31/2010 were included (search last updated 2/1/2011). Reference sections within articles that met inclusion and exclusion criteria, as well as any published literature reviews, were also considered to identify additional titles.

One reviewer (GR) independently screened titles. Abstracts of potential topic-related studies were then reviewed. When an abstract was not available or did not provide enough detail for determining inclusion, full text articles were retrieved. Studies that were eligible for inclusion for the current review included only those that reported original research findings for at least one objective measure of compliance or persistence for patients receiving any ocular hypotensive agent. Any study that reported patient or physician self-assessed (subjective) measures of compliance or persistence was examined, but was not included in the current review unless one or more objective measures was also obtained and reported within the same study.

The following types of studies were excluded from this review: (1) editorials, letters, and other commentary pieces, (2) narrative or clinical topic reviews, (3) case studies, (4) studies that had required failure on previous glaucoma therapy as an inclusion criterion for subject selection (thus containing an uncontrolled bias of regression to the mean), (5) interventional studies (such studies would typically not reflect usual care for glaucoma), unless a separate pre-interventional observation period was conducted for the entire patient sample (both study arms). Studies that selected patients who were not new to ocular hypotensive therapy or who were required to meet some minimum threshold of persistence on therapy were not excluded from this review. However, such selection rules could have affected findings and are thus separately identified by study when employed.

**Data abstraction**

The full text of included articles was reviewed. One reviewer (GR) reviewed each study and extracted information for placement in a summary table organized by objective estimation method, citation, design summary, endpoint(s) measured, patient selection/study setting, study year, and summarized study findings on these endpoints.

**Persistence and compliance findings across drug cohorts**

Several studies quantified persistence on therapy by using survival analysis methods. The primary focus of such studies was a comparison of the relative risk of time to therapy failure among products or classes of ocular hypotensive agents. Therapy failure was typically defined as discontinuation or change of therapy or both. Few such survival studies reported the proportion of patients who had failed therapy by combining all cohorts. Even among individual cohorts, few reported exact proportions of patients who had failed therapy at specific points in time (eg, at 180 days, 1-year, 2-year intervals) unless such findings were displayed as Kaplan–Meier (KM) or Cox Proportional Hazard Model plots.

We developed a method to summarize findings for the entire study sample when results were reported only by drug cohort or as KM or Cox survivor function plots. The proportion remaining persistent at 12 months from treatment start was recorded for each such study (no study had a shorter follow-up). For those whose 12-month persistence findings were available only within plots rather than in table or text, the following method was used: for each article that was not already available as an electronic file, we scanned plots from the printed copy. For all plots, Snagit 8.0 (www.techsmith.com) was used to convert a full-screen magnification of the displayed electronic graph to a high-quality JPEG graphic file. Engage Digitizer 4.1 (www.digitizer.sourceforge.net), an open-source software package designed for plot-to-data conversions, was used to translate the JPEG plot line for each cohort to a spreadsheet of persistence values, at the points where the y-axis (percentage remaining persistent) intersected the corresponding time value immediately before, through and after 12 months, as shown at the x-axis. For the 12-month time point, the mean persistence (n-weighted by drug cohort), and range of persistence values across all drug cohorts within each study were calculated and reported.

Many of the authors described the same study sample in two or more published articles. However, in each of these articles, a different analysis of that sample data was reported. For efficiency in this review, findings from multiple articles...
appearing to use the same cohort have been combined within tables into a single group of summarized findings (ie, as a single “study group”). However, two studies\textsuperscript{10,11} that analyzed a subsample from within a larger sample are considered for this review as new studies, and are separately described. Stata (Intercooled 8.0, College Station, TX) was used for statistical analysis.

Unless otherwise indicated, all measures of compliance or persistence refer to usage of the originally prescribed agent only. However, in two studies noted below, by Gurwitz et al\textsuperscript{12,13} usage of any ocular hypotensive following the initially prescribed agent was included within the compliance estimate.

**Results**

The last updated search of the PubMed database (2/11/2011) yielded 635 unique titles. This literature search and review of reference sections yielded 58 articles (comprising 49 study groups) that were deemed to have met all inclusion and exclusion criteria. These articles were categorized by measurement method and are separately listed by study group in Supplementary tables 1 (electronic monitor), 2 (prescription fills), and 3 (chart review).

Figure 1 summarizes the count of reviewed articles by publication year. Few articles were published before the year 2000. Thirty-four of the 58 articles were published between 2005 and 2010.

**Measurement of compliance – electronic monitoring**

Electronic monitoring provides a means of monitoring compliance by objectively capturing the opening and closing of a vial enclosure, or the vial itself, by study subjects over a defined follow-up period. Both the date and time for each instance of opening and closing are captured. The design of these studies is prospective; all subjects have agreed to participate. Depending on the design of the study, subjects may, or may not, have been told that usage of medication was being monitored. Because of the precise level of detail on timely usage of medication over time, this method has been referred to as the “gold standard” for compliance measurement.\textsuperscript{14,15} Limitations with electronic monitoring include the short follow-up period generally available, and the potential for introducing experimenter’s bias, both a consequence of the clinical trial-like setting of such studies. Supplementary table 1 lists the seven identified non-interventional study groups (reported in 14 articles) using electronic monitors.

Norrell, in 1979, published the earliest of all articles evaluated in this review, evaluating usage within a group of patients of a small box-like monitoring device that held a pilocarpine vial.\textsuperscript{16} This was followed by six articles\textsuperscript{17–22} reporting separate analyses of the same Swedish cohort and a separate study that analyzed a sub-sample of this larger cohort, by Granstrom (in 1985).\textsuperscript{10} Kass et al (in 1986),\textsuperscript{23,24} and Kass et al (in 1987)\textsuperscript{25} separately reported findings from two US cohorts using a smaller, integrated vial/monitoring device. Robin et al (in 2007),\textsuperscript{26} Hermann et al (in 2010),\textsuperscript{27} and Hermann et al (in 2010)\textsuperscript{28} reported findings from separate cohorts in the US, Greece, and France, respectively, each of which also used an integrated vial/monitoring device. All studies appeared to examine patients who were existing users of ocular hypotensive therapy, and all, except Robin et al,\textsuperscript{26} masked the purpose of the monitor from some or all subjects; in Hermann et al\textsuperscript{27} patients were randomly assigned to masked and unmasked cohorts. The latter study found no significant differences in among compliance endpoints between masked and unmasked cohorts.

Among all monitoring studies, the lowest rates of compliance were found in the recent Hermann et al studies;\textsuperscript{27,28} each evaluated brimonidine users. Over a 1-month period the ratios of recorded-to-intended doses across patient samples in the two countries examined were 62%\textsuperscript{28}–64%\textsuperscript{27} for thrice-daily users vs 72%\textsuperscript{28}–73%\textsuperscript{27} for twice-daily users. Kass et al reported that, over a 1-month period, only 76% of prescribed doses were taken in a study of pilocarpine users\textsuperscript{24} vs 83% in a later study of timolol users.\textsuperscript{25} Norell and Granstrom found, over a 20-day period, that 90% of prescribed doses of pilocarpine appeared to be administered (only 10% were missed).\textsuperscript{28} Robin et al found, over a 60-day period, that 97% of prescribed doses of prostaglandins were administered within 2 hours of the scheduled time.\textsuperscript{26} Despite the relatively high compliance rates found in the latter two studies, both found a substantial clustering of poor compliance behavior among certain subjects. The Norell study group found that 20% of...
subjects had intermediate (missed 10%–19% of doses) and 20% had poor compliance (missed ≥ 20% of doses), 22 while Robin et al found that 20% of subjects had poor compliance (> five errors over 20 days). 26

Measurement of compliance and persistence – prescription records review
The 36 study groups (reported in 38 articles) analyzing prescription fill records accounted for nearly two-thirds of all published articles in this review (Supplementary table 2). Many of these studies reported findings for both compliance and persistence endpoints. Many compared the relative persistence performance between various drug cohorts. Across these studies, Table 1 summarizes findings for compliance and persistence among those specific endpoints used in more than one study.

Time to therapy failure using survival analysis
All studies using survival analysis were conducted retrospectively with prescription fill or medical chart data. Since survival analysis employs censoring of subjects who are lost to, eg, follow-up through health plan or other database disenrollment, or reaching the end of the study, this method offers the advantage of including subjects without the need for a minimum available follow-up period. This method tracks for the occurrence of a “failure” event, eg, discontinuation, or discontinuation/change on therapy. This method is much less precise than electronic monitoring for identifying a sentinel deviation from scheduled therapy, and must rely on establishing criteria for defining a substantial delay or gap in refilling or re-issuing of a prescription, or the introduction of a new agent, to identify a failure event. Except in two studies described below, 29,30 this method does not typically measure whether patients return to therapy once a failure event is indentified.

As shown in Table 1, 14 studies 1,5,10–41 used survival analysis to evaluate time to therapy discontinuation from prescription fills, all but one 33 of which reported findings for patients who were stated to have evidence of being new to any ocular hypotensive therapy (ie, were assumed treatment-naïve). Across the 14 studies, a mean of 31% (range 10%–68%) of all patients had remained persistent (no discontinuation) on their initial ocular hypotensive at the end of 12 months from the start of therapy. Twelve studies used survival analysis to evaluate time to therapy discontinuation or change (eg, switch of initial agent or addition of adjunctive agent). 32,36–38,40–47 Of these, all but three 42,43,46 provided evidence that patients were treatment-naïve. Across the twelve studies, a mean of 40% (range 14%–67%) of patients remained persistent (no discontinuation or change) at 1 year. When analysis was restricted to those six studies separately reporting both discontinuation and discontinuation/change persistence rates, 32,36–38,40,47 a mean of 35% (range 19%–68%) had not discontinued and 26% (range 14%–55%) had not discontinued or changed the initially prescribed agent.

Schwartz et al 29 and Zimmerman et al 30 evaluated the subsequent disposition of patients who had discontinued therapy during the first observation year. Although only 10% of treatment-naïve patients in Zimmerman et al 30 were persistent on therapy at year’s end, 55% of the total sample had been non-persistent but later restarted therapy before the end of this year. Only 19% of the total sample had completely discontinued all ocular hypotensive therapy without evidence of restarting any therapy at the end of this year. Schwartz et al found that, of the subset of 65% of patients who discontinued therapy at

<table>
<thead>
<tr>
<th>Source</th>
<th>Endpoint</th>
<th>Mean of studies</th>
<th>SD</th>
<th>Range</th>
<th>Number of studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rx fills</td>
<td>Percentage persistent at 1 year until discontinuation of therapy</td>
<td>31%</td>
<td>17%</td>
<td>10%–68%</td>
<td>14</td>
</tr>
<tr>
<td>Rx fills</td>
<td>Percentage persistent at 1 year until discontinuation or change of therapy</td>
<td>40%</td>
<td>19%</td>
<td>14%–67%</td>
<td>12</td>
</tr>
<tr>
<td>Rx fills</td>
<td>Medication possession at end of 1st year</td>
<td>51%</td>
<td>7%</td>
<td>44%–59%</td>
<td>3</td>
</tr>
<tr>
<td>Rx fills</td>
<td>Medication possession ratio or proportion of days covered over 1st year</td>
<td>56%</td>
<td>19%</td>
<td>37%–92%</td>
<td>6</td>
</tr>
<tr>
<td>Rx fills</td>
<td>Rate of total non-adherence (no refills following start of therapy in 1st year)</td>
<td>24%</td>
<td>1%</td>
<td>23%–25%</td>
<td>2</td>
</tr>
<tr>
<td>Medical chart</td>
<td>Percentage persistent at 1 year until change (or change/discontinuation) of therapy</td>
<td>67%</td>
<td>7%</td>
<td>62%–78%</td>
<td>5</td>
</tr>
</tbody>
</table>

Notes: *Mean across studies for those endpoints that were reported in two or more reviewed Studies (within-study means were derived by n-weighting drug cohorts if a total-sample mean was not available). The denominator for of studies is the total number studies within the source category, except for two studies that reported findings for two separate cohorts: diagnosed glaucoma and glaucoma suspect* and primary open-angle glaucoma and ocular hypertension. 38 For these exceptions, both cohorts were included in both the numerator and denominator when calculating the mean of studies estimates. For Tingey et al 44 persistence findings include only the Phase 1 cohort (those starting first-line glaucoma treatment) but exclude the Phase II cohort (those who previously failed beta blocker therapy).

Abbreviation: Rx, prescription.

Table 1 Mean of compliance and persistence endpoints
day 180, only 51% of these treatment-naive patients had failed to restart therapy by the end of the observation year.29

Medication possession at 12 months for new therapy starts
Medication possession uses prescription fill records to assess whether a patient has a sufficient supply of the study drug on hand (ie, “possession”) at a given point in time, for instance at 6 months or 1 year after starting therapy. Although medication possession offers a simple method for estimating persistence, it does not provide a summary estimate of usage of the study drug for the period prior to the time point at which possession is assessed. For the three studies5,48,49 that reported medication possession at 12 months (Table 1), a mean of 51% (range 44%–59%) of all patients had a supply of the initially prescribed agent on hand at year’s end. Separately, Wilensky et al10 found, for patients who had successfully remained on therapy for at least 3 months, that 69% later had possession at 1 year. Each of the medication possession studies evaluated only patients who were new to therapy.

Proportion of days covered (PDC) and medication possession ratio (MPR)
The PDC and MPR both capture approximate days over a given period for which patients have sufficient days supply to administer therapy. Both the MPR and PDC use the same numerator, the sum of days supply of all prescription fills over the period. However, while the MPR uses the number of elapsed days from the initial fill to the final fill of a prescription over the follow-up period, the PDC uses elapsed days from initial fill until a given point in time (eg, 6 months, 12 months) after the initial fill as the denominator. For the six studies that reported MPR or PDC rates during the 12 months after therapy start (five of which evaluated treatment-naive patients),1,12,13,11,49,51 56% (range 37%–92%) of the days in the first therapy year could be dosed with the total days supply of prescriptions dispensed over this period. Separately, Friedman et al found, for treatment-naive patients, a mean MPR of 64% across a mean follow-up of 22 months.84 Wilensky et al found a PDC of 76% for patients over the first year who were treatment-naive but who had been continuously persistent on therapy for 90 days following therapy start.82 Djafari et al found that 72% of patients had a PDC ratio of ≥75% over a 2-year period, for a mix of patients new and not new to therapy.52

Other measures using prescription fills
Lee et al found that 89%, 71%, and 22% of patients (likely existing users) had at least one significant gap in therapy during a 12-month follow-up period when evaluating allowed gaps of 45, 60, and 120 days, respectively.53 Friedman et al found that 90% of treatment-naive users experienced at least one significant gap over an average 22-month follow-up period; further, 20% of all patients discontinued all ocular hypotensives, with no evidence of adding, switching, or restarting agents.48 Another study by Friedman et al reported associations of MPR with patient-reported factors in a subset of patients from this earlier study but did not report MPR estimates.54 Higginbotham et al reported that only 30% of existing or new therapy users had not changed or discontinued any ocular hypotensive agent during the 1-year period after audit of a retail pharmacy database.55 Gurwitz et al also reported that a mean of 24% of patients failed to receive a refill or fill for any ocular hypotensive agent (original or new) in the year following start of therapy in treatment-naive patients (Table 1).12,13 Muir et al reported that patients enrolled in a study of factors related to compliance had only refilled their ocular hypotensive a mean of 2.5 times during the 6 months prior to being interviewed.56,57 Robin et al found in a study of patients who were persistent with latanoprost in the year prior to receiving at least two fills of an adjunctive agent that the mean interval between refills for latanoprost increased from 40 days prior to introduction of the adjunctive agent to 47 days afterwards.58 Rotchford and Murphy reported that 51% of patients (existing users) for whom dispensing information was available did not have sufficient timolol to medicate as prescribed over the observed treatment year.58 Using a combination of prescription records and patient self-reports of non-adherence to define refill non-adherence, Stryker et al found that 67% of existing therapy users were classified as non-adherent over a non-defined observation period.59 Yousuf and Jones found that, even within an inpatient hospital setting, mean adherence rates with prescribed ocular hypotensive medication was only 67%.60

Measurement of compliance and persistence – medical chart review
As shown in Supplementary table 3, six studies11,61–65 analyzed medical chart data to estimate rates of persistence among patients receiving ocular hypotensives. All but one65 analyzed persistence on therapy using survival analysis (four in treatment-naive patients), evaluating either time to therapy change, or time to therapy discontinuation or change. Since we considered it unlikely that ophthalmologists would have discontinued therapy without replacement with some other ocular hypotensive agent, results for the five studies using either of these two persistence endpoints are combined in Table 1. Across these five studies, a mean of 67% (range 62%–78%)
of patients were shown by chart to have remained persistent with their starting therapy at the end of the first therapy year. Persistence rates in the sixth study could not be evaluated.

Discussion
As described, the number of studies employing objective assessments of compliance and persistence in glaucoma pharmacotherapy is substantial and has recently accelerated, more than doubling over the past 6 years. Interpretation of findings across many studies is made somewhat difficult by the heterogeneity of methods for measuring compliance and persistence endpoints, and in the varied patient selection criteria used in the studies reviewed. These multiple methods, when viewed in total, yield a range of perspectives for understanding compliance and persistence problems. However each must be interpreted with an understanding of its inherent limitations.

Although the electronic monitor likely comes closest to modeling actual medication use of the established ocular hypotensive user, such studies to date have yielded little understanding regarding users who are new to therapy. The short follow-up periods and clinical-trial-like designs somewhat limit attempts to generalize such findings to longer-term use in naturalistic settings. The lack of uniformity across studies in the specific endpoints used to estimate compliance from monitoring data (as shown in Supplementary table 1) perhaps more strongly limits attempts to compare findings across these studies.

While a review of prescription fill records offers the potential to greatly extend the observation period, describe actual drug use in natural settings, and employ standardized compliance and persistence measures, many methodological questions are left unanswered. For instance, does the days supply reported on the prescription fill record reflect the actual coverage required given what is not revealed: the patient’s ability to avoid wastage, whether a patient treats one or both eyes, the actual number of drops available in a given vial, and the effect of drug samples on these estimates?

The medical chart comes closest to what is available to the ophthalmologist as a practical tool for monitoring and perhaps correcting persistence problems with therapy, but this too has limitations. Although the prescribing physician should be aware of changes to therapy since he/she likely authorizes them, little is revealed from the chart whether a patient is compliant and persistent on a prescribed ocular hypotensive unless the patient so informs the physician or fails to request timely refills. Further, once a patient is lost to medical follow-up for failing to reschedule visits, all remaining persistence data for that patient become lost as well.

Many methodological issues found in this review appear to be independent of measurement method. For instance, many studies selected only patients who were treatment-naïve. Others evaluated existing ocular hypotensive users or a mix of the two groups. This is an important consideration for interpretation of findings, particularly since differences in compliance and persistence could be expected across these selected groups. Patients who are existing therapy users are by definition more experienced and are largely therapy survivors, having refilled at least one prescription. These users would be expected to be more likely to properly consume their initial therapy when compared those just starting therapy.

Despite design limitations among methods, much has been learned from the body of empirical research evaluated in this review. By comparing every scheduled to actual administered dose, the electronic monitor studies provide uniquely precise estimates of daily medication-taking behavior by established ocular hypotensive users. Thus, of the most commonly used glaucoma agents today, the prostaglandins and beta blockers, findings from the electronic monitor studies suggest that compliance behavior remains a problem for a substantial proportion in existing users, perhaps one in five to one in four. These studies also suggest a general trend toward greater compliance with fewer required doses per day, clearly established in Hermann et al. and suggested with the improved compliance observed in the timolol and prostaglandin studies compared with the thrice-daily regimens of brimonidine and pilocarpine.

The greatest strength of survival analysis-based persistence studies from prescription records is the sheer volume of evidence that most patients (perhaps two in every three) who are new to ocular hypotensive therapy will have a substantial gap in refilling their initially prescribed agent in the first year of therapy. Analysis of persistence data from medical charts suggests that perhaps one of every three patients would have undergone a change in agents, either as a switch or addition of an adjunctive agent. Accounting for this difference would yield a net count of one in three patients who had started therapy but had discontinued (without change in agents) by the end of the first therapy year. What became of therapy for these patients? Zimmerman et al. and Schwartz et al. suggest that approximately half of these would have resumed their originally prescribed therapy after this significant therapy failure or gap. A limitation of survival studies is that little is known about continued persistence on therapy for those patients who are either switched to a new agent or who return to their initial agent after a substantial gap.

Like the survival analysis, medication possession assesses persistence on therapy at a given point in time (though it lacks...
consideration of patients who are lost to follow-up). For new ocular hypotensive users, only half will have an apparent supply of the initially prescribed agent on hand at the end of the first therapy year. This improves considerably for “therapy survivors” who achieve initial persistence through first 90 days (two-thirds of these have possession at year’s end). Further, many patients, perhaps one in four, appear to simply fail to refill for any ocular hypotensive agent even once after starting therapy.

Although both PDC and MPR are unable to measure deviations from scheduled doses, they do offer a simple and approximate measure of days of therapy coverage or drug availability in a naturalistic setting. The low combined PDC/MPR value of 56% for the five studies that reported year-end values appears equally poor compared with the MPR of 64% reported in the recent large-scale study of Friedman et al across an average follow-up of 22 months. These findings further suggest that a failure to refill or sporadic refilling of ocular hypotensives is common among patients.

Unlike evidence from electronic monitoring studies of compliance, persistence with ocular hypotensive therapy does not appear to be improving with the increased availability of once-daily dosing regimens. In Friedman et al’s analysis of claims data over the period 1999–2005, a time when once-daily prostaglandins or beta blockers were available and heavily prescribed, few patients over the 22-month follow-up did not have at least one substantial gap in refilling; 20% discontinued filling of ocular hypotensives altogether.

**Summary and recommendations**

Despite the greater attention devoted to this issue in recent years, empirical evidence provided in this review suggests that poor compliance remains common for many glaucoma patients who are existing ocular hypotensive users. Both compliance and persistence remain problems for those who are new to such therapy.

For those new to therapy, active engagement with the patient by the ophthalmologist, physician assistant, nurse, or pharmacist is especially important in the first treatment year. Assessment should include discussion of compliance and persistence behavior, and eliciting of patient-perceived problems such as tolerability, forgetting doses, or the taking of drug holidays. Also, some evidence suggests that encouraging the patient to remain compliant with the scheduling of visits may help medication compliance. Both Gurwitz et al and Jayawant et al found that patients who had a higher count ofophthalmologist visits in the first year also had higher rates of ocular hypotensive compliance and persistence, respectively. Quigley et al found that missing an ophthalmology visit was associated with lower compliance with therapy.

For existing therapy users, who are more experienced, often using adjunctive therapy to control their glaucoma, important considerations, besides missing scheduled doses, are dyscompliance concerns (wrong or unsuccessful use of eyedrops). In one study 44% of patients reported regularly missing the eye when applying drops. Another study found that less than one-third of observed instillations in existing users were performed successfully, with 17%–25% of patients unable to place a drop in their eye. Several of the electronic monitoring studies in this review found evidence pointing to dyscompliance. In Kass et al the weight of the pilocarpine vial utilized during the study was only weakly correlated with therapy compliance, which suggests that greater drug consumption may not be a good predictor of appropriate drug use. Hermann et al found that some patients required up to 3.7 drops per scheduled dose per eye, implying the emptying of a full vial in as little as a week. Robin et al found, in subjects using beta-blockers as adjunctive therapy, that 25% of the intervals between beta blocker doses were 10 hours or lower (suggesting a potential safety issue).

Gray et al, in their recent Cochrane review, examined randomized interventions to improve adherence to ocular hypotensive therapy. Only eight eligible randomized intervention studies published until the review year 2009 were deemed as evaluable. These authors concluded that simplified dosing regimens, reminder devices, education, and individualized care planning showed improvements in adherence rates. Adequately controlled and designed interventions that may be especially worthwhile to pursue would include: structured but interactive patient educational programs, strategies to improve physician communication, and the integration of drug with compliance device. Ocular hypotensive agents may have the highest potential for effectiveness and lowest levels of adverse effects, when delivered with dosing aids and adherence devices (see Kahook).

Although more empirical studies to identify the scope of compliance and persistence problems might help track whether progress is being made, there is little need for further objective assessment in the near-term to confirm that such problems continue to exist. Building upon a legacy of more than 40 years of subjective and objective assessments, the direction of empirical compliance and persistence research in glaucoma should rapidly shift toward solutions: (1) performing rigorous and quantifiable assessments of likely root causes of non-compliance and non-persistence, to identify areas for intervention, (2) developing validated, physician-usable risk-assessment
tools to monitor and predict non-compliance, (3) evaluating promising compliance-improvement interventions with strong study designs to compensate for the limited randomized-trial research to date, and (4) further expanding the eight clinical recommendations proposed by Olthoff et al into a formalized set of guidelines for the recognition and treatment of patients who are potentially non-compliant or non-persistent.

**Acknowledgments/Disclosures**

The study was supported by Pfizer Inc, New York, NY, USA. GR is an employee of Informagenics, LLC who were paid consultants to Pfizer, and GFS was a paid consultant to Pfizer, both in connection with the design and conduct of the study, and development of the manuscript. SK is an employee of Pfizer Inc. GR and SK acquired, analyzed, and interpreted the data. All authors were involved in drafting the manuscript and/or revising it critically. All authors read and approved the final manuscript.

**References**


60. Yousuf SJ, Jones LS. Adherence to topical glaucoma medication during hospitalization. J Glaucoma. 2010. [Epub ahead of print]


Table S1 Measurement of compliance – electronic monitoring studies

<table>
<thead>
<tr>
<th>Study group</th>
<th>Design/cohorts</th>
<th>Endpoint</th>
<th>Patient/setting</th>
<th>Study year</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granstrom10</td>
<td>Retrospective observational&lt;br&gt;1) Electronic medication monitor data&lt;br&gt;2) Chart review.&lt;br&gt;Subjects were blinded from the purpose of the monitor. Single cohort: pilocarpine (TID)</td>
<td>See description of endpoints below in Norell/Granstrom</td>
<td>56 of 82 subjects from Norell16 who were followed for 2 years before and after the electronic monitor observation period</td>
<td>Not specified</td>
<td>Compared with those having no progression, those with progression of visual field defects during the 2-year pre-monitor period had a lower rate of “good-intermediate” (50%) vs “poor” compliance (58%) during the 20-day monitor assessment. In the non-interventional group (n = 26) followed for 2 years after monitor observation, those with progression of visual field defects, in the post-monitor period had a higher rate of “good-intermediate” (63%) vs “poor” compliance (30%) observed at the time of the monitor. Neither finding was significant. There was a statistically significant association between type of glaucoma, stage of visual field defects, and mean IOP. When these factors were adjusted for, the difference in proportion of patients with visual field defect progression in those with “good” vs “poor” compliance was reduced for both 2-year pre- and post-monitor periods</td>
</tr>
<tr>
<td>Hermann27</td>
<td>Prospective observational. Electronic medication monitor data. Subjects were randomly assigned to masked (ie, blinded) and unmasked monitoring. Random assignment to BiD or TID dosing. Single cohort: brimonidine</td>
<td>Over 4 weeks, A) Number of recorded application events per 24-hour period B) Time interval between doses C) Ratio of recorded to intended dose events (adherence) D) Proportion of time for which recorded dose was not exceeding intended dose by &gt;3 hours (coverage)</td>
<td>36 subjects who were 18+ years with diagnosis of POAG or OHT, prescribed brimonidine BID to TID at university glaucoma clinic [Greece]</td>
<td>Not specified</td>
<td>Differences between means of masked vs unmasked monitoring for 1–4 were not significant when stratified by regimen (BiD, TID)</td>
</tr>
<tr>
<td>Hermann28</td>
<td>Prospective observational. Electronic medication monitor data. All subjects were masked from purpose of the monitor. Random assignment to BiD or TID dosing. Single cohort: brimonidine</td>
<td>Over 4 weeks, A) Number of recorded application events per 24-hour period B) Time interval between doses C) Ratio of recorded to intended dose events (adherence) D) Proportion of time for which recorded dose was not exceeding intended dose by &gt;3 hours (coverage) E) Amount of medication used per dosing event F) Mean number of drops applied per dosing event</td>
<td>75 subjects who were 18+ years with diagnosis of OAG, angle closure or OHT, receiving topical glaucoma therapy [France]</td>
<td>Not specified</td>
<td>A) BID mean = 1.44 (SD = 0.4), TID 1.86 (0.5) Sig B) BID 17.5 (4.4) hours, TID 13.2 (2.5) hours Sig C) BID 73.3% (13%), TID 64.0% (15%) Sig D) BID 71.8% (12%), TID 69.3% (9.5%) NS E) Treat 1 eye 69 (3.1) mg, treat both eyes 97 (3.3) mg Sig F) Treat 1 eye 1.7 (0.7), treat both eyes 2.4 (1.5) Sig. On average 20% of medication was wasted due to using &gt;1 drop per eye per dosing</td>
</tr>
</tbody>
</table>

(Continued)
### Table S1 (Continued)

<table>
<thead>
<tr>
<th>Study group</th>
<th>Design/cohorts</th>
<th>Endpoint</th>
<th>Patient/setting</th>
<th>Study year</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kass23,24</td>
<td>Prospective observational</td>
<td>1) Percentage of doses taken as recorded by the monitor over 30 days 2) One or more questions on compliance behavior at the end of the 30-day period 3) Estimated number of doses that subject would omit over next 30 days 4) Pre- vs post-observation difference in vial weight 5) Subject daily diary of administration times</td>
<td>184 subjects who were 18+ years, currently prescribed pilocarpine QID for IOP reduction, from private practices of university faculty [Washington in US]</td>
<td>1981–1984</td>
<td>1) For all subjects, mean of 76.0% (SD = 24.3%) of prescribed doses. 15.2% of all patients took &lt; 50% of prescribed doses, 34.2% took &lt; 75% of doses. Mean rate of compliance was higher (87.6% [27.8%] Sig) in the 24-hour period preceding the return appointment than over the entire 30-day observation period. IOP on day 30 return visit did not significantly correlate with compliance prevalence. 2) Subjects reported that they were taking a mean of 97.1% (5.9%) of prescribed doses. Correlation between patient-reported compliance and monitor data was modest ($r = 0.203$) Sig23 3) Mean physician estimate of compliance was 79.4% (14.9%). Correlation between physician estimates of compliance and medication monitor estimates was modest, with a correlation coefficient of $r = 0.20$ Sig23 4) Modest correlation ($r = 0.18$) Sig occurred between vial weight difference and monitor estimates23 5) Mean reported rate of compliance was 98.9% (1.8%). Correlation between daily log and monitor data was modest ($r = 0.24$, NS)23 The entire group administered a mean of 82.7% (SD = 19.0%) of prescribed doses. 8.2% of all patients took less than 50% of prescribed doses, and 27.3% took &lt; 75% of doses. 60 of the 110 patients were receiving timolol alone vs those receiving pilocarpine or another agent along with timolol. The rate of compliance with timolol was lower among patients receiving timolol alone vs those receiving timolol plus another agent NS</td>
</tr>
<tr>
<td>Kass25</td>
<td>Prospective observational. Electronic medication monitor data. All subjects were masked from purpose of the monitor. Single cohort: pilocarpine</td>
<td>Compliance was defined as the percentage of timolol doses taken, as recorded by the monitor over 30-day period</td>
<td>110 subjects who were 18+ years, prescribed timolol BID for IOP reduction from private practices of university faculty [Washington in US]</td>
<td>1984–1985</td>
<td>1A) Patients missed at least 1 dose during 23% of all days. Of these, 19% occurred at the 1st, 54% at the 2nd, and 27% at the 3rd scheduled dose during the day. 1B) 10% of the doses prescribed were missed. Patients missed at least 1 dose during 23% of all days. Of all 60 expected doses, 59% of patients missed 0%–9% (had good compliance), 20% missed 10%–19% (had intermediate compliance), and 20% missed 20% (had poor compliance). 1C) 1% of doses were extra doses. 1D) For a median of 17.2% (range 3%–8%) of the observed time, the time since the previous dose had exceeded 8 hours.</td>
</tr>
<tr>
<td>Norell-Granstrom16–22</td>
<td>Prospective observational</td>
<td>1A) Number of days where &lt; 3 dosages were self-administered over 20-day period 1B) Proportion of missed doses (of 60 possible) over 20 days 1C) Proportion of extra doses (of 60 possible) over 20 days 1D) Proportion of time over 20-day period for which scheduled dosing time was exceeded 2) Immediate post-monitor subject estimate of compliance during intervention phase of study are reported here. All subjects were masked</td>
<td>82 subjects, aged 56–90 years, treated at eye clinic at Huddinge University Hospital, with POAG, visual defects, cupping, IOP 21+ mmHg, visual acuity 2/60, and currently using pilocarpine TID [Sweden.]</td>
<td>1977–1978</td>
<td>1A) Number of days where &lt; 3 doses were self-administered over 20-day period 1B) Proportion of missed doses (of 60 possible) over 20 days 1C) Proportion of extra doses (of 60 possible) over 20 days 1D) Proportion of time over 20-day period for which scheduled dosing time was exceeded 2) Immediate post-monitor subject estimate of compliance during intervention phase of study are reported here. All subjects were masked</td>
</tr>
</tbody>
</table>
from purpose of the
monitor. Single cohort:
pilocarpine (TID)

past 7 days compared with
medication monitor data

physician and assistant estimates
of estimates of compliance
independent of knowledge
from 1) and 2) above

453

Compliance and Persistence in Glaucoma

2) 4% of patients said they missed 2+ doses over past
week, compared to medication monitor results
showing that 33% missed 2+ doses

3) Correlation between physician estimates of
compliance and medication monitor estimates was
poor, with a correlation coefficient of $r = 0.19$ NS

Prospective, single-site,
open-label, non-randomized,
parallel design. Electronic
medication monitor data.
Subjects were not masked from
purpose of the monitor.
Cohorts: prostaglandin
(QD) as monotherapy
(1-drug group), prostaglandin
with an adjunctive
medication (2-drug group)

Over a 60-day observation period
A) Over/underadherence of the
number of doses per 24-hour
period, compared to nominal
dosing: adherers (0–2 errors),
marginal (3–5 dosing errors),
and poor (>5 errors)

B) Proportion of time for which
interval between doses
was <2 hours more than
nominal dosing interval
(coverage)

C) Interval between doses
(interdose interval)

D) Number of doses divided by the
number of days in study, times
the prescribed dosing frequency
(% of doses taken)

62 subjects at a private,
subspecialty glaucoma practice,
18+ years with OAG or OHT,
stable IOP for 30+ days, using
either a single prostaglandin or
prostaglandin plus adjunctive agent

Not specified

A) Overall, 20% of all subjects were in the poor
category. For subjects in the 1-drug group, only 3.3%
were in the poor category. For subjects in the 2-drug
group, 10.0% were in the poor category for the
prostaglandin and 30.0% were in the poor category
for adjunctive therapy

B) For the prostaglandin, the mean coverage was 97.2%
(SD = 6.1%). It was similar in both the 1-drug group
(97.5% [3.9%]) and the 2-drug group (96.8% [6.2%]).
For adjunctive medications, the mean coverage was
slightly less: 93.0% (8.3%)

C) For the prostaglandin, the mean interval between
doses was 24.4 (1.2) hours. When stratified by
number of medications, the 2 groups were similar,
24.3 (1.2) hours for the 1-drug group vs 24.4
hours (1.3) for the 2-drug group. For adjunctive
medications, the mean interval between doses was
22.7 (2.1) hours for QD dosing, 12.4 (1.4)
hours for BID dosing, and 8.2 (0.2) hours for TID
dosing

D) For the prostaglandin, subjects took 97.0% (6.7%)
of doses prescribed. The proportion of doses taken
was similar when stratified by 1-drug [96.5% (4.7%)]
or 2-drug [97.5% (8.2%)] groups. For the adjunctive
medications (2-drug subjects only), subjects took
99.9% (13.0%) of doses prescribed

Abbreviations: BID, twice daily; IOP, intraocular pressure; NS, not significant at 95% confidence; OAG, open-angle glaucoma; OHT, ocular hypertension; POAG, primary open-angle glaucoma; QD, once daily; QID, 4 times daily; TID, 3 times daily; $r$, correlation coefficient; SD, standard deviation; Sig, significant at 95% confidence; TID, 3 times daily.
<table>
<thead>
<tr>
<th>Study group</th>
<th>Design/cohorts</th>
<th>Endpoint</th>
<th>Patient/setting</th>
<th>Study year</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhosle31</td>
<td>Retrospective observation using Rx claims. Cohorts: latanoprost, non-latanprost agents</td>
<td>A) Persistence: time to Tx DC (60-day [1 bottle], 120-day [2 bottle] gaps) B) Adherence: MPR was calculated as the total days supply divided by the number of days between the index date and the dispensing date of the last prescription in the first Tx year</td>
<td>268 patients, 65+ years, new to glaucoma therapy, with POAG diagnosis in a Medicaid HMO [Southeastern US]</td>
<td>2000–2002</td>
<td>A) Mean (range) of persistence of cohorts at 1 year: 25% (18%–29%) B) Mean (range) of adherence of cohorts at 1 year: 44% (0.40%–0.51%)</td>
</tr>
<tr>
<td>Dasgupta32</td>
<td>Retrospective observation using Rx claims. Cohorts: beta blockers, brimonidine, carbonic anhydrase inhibitors, latanoprost</td>
<td>A) Time to Tx DC [120-day gap] B) Time to DC or change</td>
<td>1330 patients, &lt;65 years and newly treated for glaucoma, in various health plans [US]</td>
<td>1999–2000</td>
<td>Mean (range) of persistence of cohorts at 1 year: A) 68% (51%–79%) B) 55% (33%–64%)</td>
</tr>
<tr>
<td>De Natale42</td>
<td>Retrospective observation using Rx records and electronic medical record. Cohorts: travoprost, latanoprost + timolol</td>
<td>Time to treatment failure, defined as prescription change (replace or DC initial therapy or add another agent) or receiving laser therapy or glaucoma surgery</td>
<td>815 patients in GPRD database. Had glaucoma diagnosis or glaucoma surgery, follow-up duration of 6 months, and first-line treatment with study agent [United Kingdom]</td>
<td>2002–2005</td>
<td>Mean (range) of non-failure rate of cohorts at 1 year: 67% (61%–69%)</td>
</tr>
<tr>
<td>Denis43</td>
<td>Retrospective observation using Rx records and electronic medical record. Cohorts: alpha-2 agonists + prostaglandin, carbonic anhydrase inhibitor + prostaglandin</td>
<td>Treatment failure, defined as prescription change (replace or DC initial therapy or add another agent) or receiving laser therapy or glaucoma surgery</td>
<td>6176 patients in GPRD database. Had glaucoma or OHT diagnosis, glaucoma surgery or glaucoma medication; follow-up duration of 6 months, and new to a cohort Tx [United Kingdom]</td>
<td>Not specified</td>
<td>Mean (range) of non-failure rate of cohorts at 1 year: 40% (34%–41%)</td>
</tr>
<tr>
<td>Djafari52</td>
<td>1) Retrospective observation using Rx utilization data 2) Patient interview 3) Treating ophthalmologist assessment Cohorts: prostaglandins, beta blockers, carbonic anhydrase inhibitors, adrenergic agents, miotics, beta blocker combinations</td>
<td>1) Adherent if number of days covered was ≥75% over 2 years 2) Single question on adherence 3) Perceived adherence status of treated patient</td>
<td>181 patients at ophthalmology clinic treated for POAG, OHT or were glaucoma suspects, and covered by RAMQ provincial insurance program [Quebec in Canada]</td>
<td>2004</td>
<td>1) 71.8% of patients were adherent (across all cohorts) 2) 88.3% of patients reported being adherent to glaucoma treatment (when asked if they used their medication as prescribed [recall period not specified]) 3) 74.6% of patients were described by ophthalmologist as being at least 75% adherent. Although 72.1% of patients thought by physician to be adherent were actually adherent, 71.1% of patients thought by physician to be non-adherent were actually adherent</td>
</tr>
</tbody>
</table>
Friedman (2009). GAPS [This article is the reference source for the GAPS methodology]
1) Retrospective observation using Rx claims
2) Phone interviews with ophthalmologists
3) Phone interviews with patients
4) Chart review: compliance findings reported only for 1) above.
No drug cohorts

Friedman (2009). See study above

IA) MPR as linear score and
IB) Gap analysis (60-day [2.5 mL], 90-day [5 mL], 120-day [2.5 mL])
IC) Medical possession at 12 months

13,977 patients, 40+ years, with OAG and new to glaucoma Tx, seen by surveyed physician [US]
1999–2005

Over a mean follow-up period of 22 months,
IA) Mean MPR of 0.64 (range 0.01–3.7)
IB) 10% used the originally prescribed prostaglandin without any gaps (were continually persistent) in refilling the prescription. Slightly more than half (54%) of the subjects had a gap in refilling the index drug but restarted after the gap. 16% switched from the index drug to another drug, and 20% discontinued all glaucoma medications without adding, switching, or restarting
IC) 59% had an ocular hypotensive in hand at the end of first Tx year. Despite required absence of glaucoma medication in the medical and pharmacy claims database in the pre-index period, 31% of subjects whose charts were surveyed had actually been treated with ocular hypotensive agents

IA) Mean not reported. Eight variables obtained from interview were associated independently with a lower MPR (P < 0.05): (1) hearing all of what you know about glaucoma from your doctor (compared with some or nothing); (2) not believing that reduced vision is a risk of not taking medication as recommended; (3) having a problem paying for medications; (4) difficulty while traveling or away from home; (5) not acknowledging stinging and burning; (6) being non-white; (7) receiving samples; and (8) not receiving a phone call visit reminder
IB) Frequency distribution not reported

(Continued)
Table S2 (Continued)

<table>
<thead>
<tr>
<th>Study group</th>
<th>Design/cohorts</th>
<th>Endpoint</th>
<th>Patient/setting</th>
<th>Study year</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gurwitz12</td>
<td>Retrospective observation using Medicaid Management Information System database. No drug cohorts</td>
<td>A) Total non-adherence, defined as no filled Rx for any Tx (topical or systemic) during the 12 months following first Rx for a topical Tx B) Days without therapy, defined as cumulative number of days during which patient did not have glaucoma medication available in the 12 months following first Rx</td>
<td>2440 patients, 65+ years of age, newly initiated on ocular hypotensive for glaucoma, enrolled in Medicaid [New Jersey in US]</td>
<td>1980–1987</td>
<td>A) 23.3% (95% CI = 21.6%, 25.0%) of patients were non-adherent within the first 12 months after initial fill B) Mean number of days without therapy in the 12-month observation period was 112 (SD = 111.6)</td>
</tr>
<tr>
<td>Gurwitz13</td>
<td>Retrospective observation using Rx claims. No drug cohorts</td>
<td>Same endpoints described above</td>
<td>616 patients newly initiated on therapy to treat OAG. Had at least 1 prescription fill of a topical medication and 15 months of eligibility in group HMO [Massachusetts in US]</td>
<td>1987–1990</td>
<td>A) 24.7% (95% CI = 21.3%, 28.1%) of patients were non-adherent within the first 12 months after initial fill. B) Mean number of days without therapy in the 12-month observation period was 30.7 (SD = 57.0)</td>
</tr>
<tr>
<td>Higginbotham55</td>
<td>Retrospective observation using Rx fills. Cohorts: single-bottle dorzolamide/timolol fixed combination, 2-bottle combination of beta blocker and second agent, 3-bottle combination of any 3 agents</td>
<td>Persistence: time until a prescription for an additional agent occurred during 12-month follow-up period (all cohorts) or 1 of agents in multiple-bottle cohorts was no longer dispensed</td>
<td>37,979 patients identified from national retail pharmacy database who had any prescription fill during a single month that matched 1 of the 3 study cohorts [US]</td>
<td>2004</td>
<td>Mean (range) of persistence of cohorts at 1 year: 30% (24%–35%)</td>
</tr>
<tr>
<td>Jayawant33</td>
<td>Retrospective observation using Rx claims. No drug cohorts</td>
<td>Persistence: time to DC, for prostaglandins (60 days [≥2.5 mL], 90 days [≥2.5 to ≤5 mL], 120 days [≥5 mL]), for other medications (60 days [≥10 mL], 90 days [≥10 to ≤15 mL], 120 days [≥15 mL])</td>
<td>268 subjects, aged 65+ years in a Medicare HMO with 2+ years of follow-up with POAG diagnosis and receiving glaucoma prescription [US]</td>
<td>2000–2002</td>
<td>Mean of persistence of cohorts at 1 year: 34%</td>
</tr>
<tr>
<td>Lafuma44</td>
<td>Retrospective observation using Rx records and electronic medical record. Cohorts: travoprost, dorzolamide + timolol</td>
<td>Treatment failure, defined as prescription change (replace or DC initial therapy or add another agent) or receiving laser therapy or glaucoma surgery</td>
<td>1026 patients in GPRD database. Had glaucoma diagnosis or glaucoma surgery, follow-up duration of 6 months, and new to antiglaucoma Tx [United Kingdom]</td>
<td>Not specified</td>
<td>Mean (range) of non-failure rate of cohorts at 1 year: 67% (62%–70%)</td>
</tr>
<tr>
<td>Lafuma45</td>
<td>Retrospective observation using Rx records and electronic medical record. Cohorts: carbonic anhydase inhibitor + beta blocker, alpha-2 adrenergic agonist + beta blocker</td>
<td>Same endpoints described above</td>
<td>6745 patients in GPRD database. Had glaucoma diagnosis or glaucoma surgery, follow-up duration of 6 months, and new to antiglaucoma Tx [United Kingdom]</td>
<td>Not specified</td>
<td>Mean (range) of non-failure rate of cohorts at 1 year: 42% (36%–43%)</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Methodology</td>
<td>Endpoints</td>
<td>Study Population</td>
<td>Duration</td>
<td>Results</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>-----------</td>
<td>-----------------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>Lafuma</td>
<td>Retrospective observation using Rx records and electronic medical record. Cohorts: brimonidine, brinzolamide</td>
<td>Same endpoints described above</td>
<td>2657 patients in GPRD database. Had OAG diagnosis or glaucoma surgery, follow-up duration of 6 months, and receiving antiglaucoma therapy (may not be Tx-naïve) [United Kingdom]</td>
<td>Not specified</td>
<td>Mean (range) of non-failure rate of cohorts at 1 year: 46% (44%-52%)</td>
</tr>
<tr>
<td>Lee</td>
<td>Retrospective observation using pharmacy database. No drug cohorts</td>
<td>Proportion of patients who had a gap during during the first year (45-day, 60-day, or 120-day gaps)</td>
<td>94,417 patients at retail pharmacies, had single fill of 2.5 mL size prostaglandin during 4Q2002 and had same product and 2.5 mL size filled 4Q2003 [US]</td>
<td>2002</td>
<td>Percentages of patients with no annual gaps in therapy at 365 days were 10.6%, 28.6%, and 77.5% for refill periods of 45, 60, and 120 days, respectively</td>
</tr>
<tr>
<td>Muir</td>
<td>1) Retrospective observation using Rx claims 2) Personal interviews with subjects. No drug cohorts</td>
<td>Refill rates over 6-month period prior to subject recruitment</td>
<td>142 subjects with a diagnosis of OAG from the Duke University Eye Center treated at practices of four glaucoma specialists [North Carolina in US]</td>
<td>2000–2001</td>
<td>I) Mean number of refills requested over 6 months for each prescribed medication was 2.5 (SD = 1.8). There was no significant association between Trust in Physician Score and the number of refills. There was a significant positive relationship between the Health Literacy Score (Rapid Assessment of Adult Literacy in Medicine) and the number of refills</td>
</tr>
<tr>
<td>Nordstrom</td>
<td>Retrospective observational using Rx claims. Cohorts: beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, prostaglandins</td>
<td>A) Persistence: time to DC (60-day ([ \leq 10 \text{ mL}]), 90-day ([ &gt; 10 \leq 15 \text{ mL}]), 120-day ([ &gt; 15 \text{ mL}]) gaps) or change B) Adherence: having current refill of index Tx at 6-month intervals</td>
<td>5300 patients, 30+ years, newly diagnosed with OAG or glaucoma suspect, new to therapy, United Healthcare [US]</td>
<td>1995–2001</td>
<td>A) Mean (range) of persistence of cohorts at 1 year: 20% (10%-38%) for diagnosed glaucoma, 16% (10%-33%) for glaucoma suspect B) Mean (range) of adherence at 1 year: 53% (38%-65%) for diagnosed glaucoma, 44% (32%-56%) for glaucoma suspect Across all cohorts and study years (1994–2004), persistence was 67%. The mean percentage persistent at 1 year rose after 1997 when prostaglandins were introduced, from 61% in 1994–1996 to 70% in 2002–2004</td>
</tr>
<tr>
<td>Owen</td>
<td>Retrospective observational using Rx records and electronic medical record. Cohorts: beta blockers, prostaglandins</td>
<td>Time to DC 90 days (any ocular hypotensive)</td>
<td>5670 patients in DIN-LINK database, started on treatment for glaucoma or OHT and new to therapy [United Kingdom]</td>
<td>1994–2004</td>
<td>(Continued)</td>
</tr>
<tr>
<td>Study group</td>
<td>Design/cohorts</td>
<td>Endpoint</td>
<td>Patient/setting</td>
<td>Study year</td>
<td>Findings</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Quigley66</td>
<td>GAPS 1) Retrospective observation using Rx claims 2) Phone interviews with ophthalmologists 3) Phone interviews with patients (4) Chart review. Compliance findings reported only for 1) above. No drug cohorts.</td>
<td>MPR as linear score</td>
<td>300 patients who had available pharmacy and chart data, 40+ years, seen by surveyed physician, with OAG and new to glaucoma therapy [US]</td>
<td>2000–2005</td>
<td>This article reports demographics and clinical characteristics for a subset of GAPS study participants who had both pharmacy and chart data. MPR findings were not reported. See Friedman 2007 study group above for MPR findings from the larger GAPS sample.</td>
</tr>
<tr>
<td>Rait35</td>
<td>Retrospective observational using Rx claims. Cohorts: prostaglandins, dorzolamide-timolol, beta-blockers, alpha-agonists or carbonic anhydrase inhibitors</td>
<td>Time to DC (90-day gap)</td>
<td>357,099 patients comprising 2 cohorts: 1) Population new to this ocular hypotensive agent and 2) New to any agent [Australia]</td>
<td>1999–2005</td>
<td>New to any eyedrop mean (range) of persistence of cohorts at 1 year: 36% (22%–56%) in year 2002, 39% (20%–55%) in year 2003. New to this eyedrop mean (range) of persistence of cohorts at 1 year: 29% (6%–50%) in year 2002, 30% (6%–51%) in year 2003.</td>
</tr>
<tr>
<td>Reardon29,36</td>
<td>Retrospective observational using Rx claims. Cohorts: bimatoprost, latanoprost, travoprost</td>
<td>A) Time to DC (90-day [1 bottle] and 180-day [2 bottles] gap) B) Time to DC or Tx change</td>
<td>4356 patients, 20+ years, new to Tx, enrolled in commercial HMO, PPO, or Medicare-risk plans [US]</td>
<td>2001–2002</td>
<td>Mean (range) of persistence of cohorts at 1 year: A) 19% (14%–23%); B) 14% (10%–17%). Of a subset of 2503 patients who had not changed ocular hypertensive therapy or disenrolled from the health plan at day 180, 65% were estimated to have discontinued therapy before the end of the year. Of these, 51% failed to restart any ocular hypertensive therapy before the end of the study at day 360 or their plan enrollment.</td>
</tr>
<tr>
<td>Reardon37</td>
<td>Retrospective observational using Rx claims. Cohorts: betaxolol, bromonidine, dorzolamide, latanoprost, timolol</td>
<td>A) Time to DC (120-day [1 bottle] and 180-day [2 bottles] gap) B) Time to DC or Tx change</td>
<td>2850 patients, 20+ years, new to Tx, covered by large New England insurer [US]</td>
<td>1999–2001</td>
<td>Mean (range) of persistence of cohorts at 1 year: A) 40% (28%–55%); B) 29% (17%–40%)</td>
</tr>
<tr>
<td>Reardon41</td>
<td>Retrospective observational using Rx claims. Cohorts: betaxolol, bimatoprost, brimonidine, dorzolamide, latanoprost, timolol, travoprost</td>
<td>A) Time to DC (90-day [1 bottle] and 180-day [2 bottles] gap) B) Time to DC or Tx change</td>
<td>28,741 patients, 20+ years, new to Tx, enrolled in commercial HMO, PPO, or Medicare-risk plans [US]</td>
<td>1996–2002</td>
<td>Mean (range) of persistence of cohorts at 1 year: A) 22% (8%–33%); B) 15% (6%–23%)</td>
</tr>
</tbody>
</table>
### Compliance and persistence in glaucoma

<table>
<thead>
<tr>
<th>Author</th>
<th>Study Type</th>
<th>Methods</th>
<th>Cohorts</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reardon&lt;sup&gt;49&lt;/sup&gt;</td>
<td>Retrospective observational using Rx claims. Cohorts: bimatoprost, latanoprost, travoprost</td>
<td>A) Medication possession at the end of year (currently taking Tx) B) Days covered in first therapy year (sum of adjusted days supply all 1st-year Rxs)</td>
<td>7873 patients new to Tx, glaucoma-related condition in commercial and Medicare-risk plans in HMO or PPO [US]</td>
<td>2004 A) Medication possession at the end of year was 28% (unadjusted pharmacy-reported days supply) and 47%–48% (adjusted days supply) B) Days covered in first therapy year was 131 (unadjusted days supply) and 228–236 (adjusted days supply)</td>
</tr>
<tr>
<td>Robin&lt;sup&gt;14&lt;/sup&gt;</td>
<td>Retrospective observational using Rx claims. Cohorts: latanoprost users who remained on monotherapy, latanoprost users who added a second medication</td>
<td>For each patient, the mean number of days between latanoprost refills was calculated for both the period before and that subsequent to the addition of the second medication (if any). The difference in means between the 2 periods was calculated</td>
<td>1784 patients who were persistent for 1 year on latanoprost from index date, received 2+ fills of latanoprost then 2+ fills of 2nd agent, and were enrolled 12+ months in a large national health plan [US]</td>
<td>2001–2002 Mean refill intervals were 40.6 (SD = 21.8) days for latanoprost before the addition of a 2nd medication and 47.4 (24.4) days after the addition of a 2nd medication, with a significant mean increase of 6.7 (25.6) days. The latter interval was longer than that found for the 3146 patients who continued on latanoprost monotherapy, who had a mean refill interval of 41 (24) days</td>
</tr>
<tr>
<td>Rotchford&lt;sup&gt;50&lt;/sup&gt;</td>
<td>Retrospective observational and survey design. 1) Rx fills review 2) Self-administered mailed questionnaire. Cohort: timolol</td>
<td>1) How frequently and what volume of monthly repeat prescriptions for timolol were dispensed over 12-month period 2) Single question on compliance</td>
<td>86 respondents, 55+ years, in 3 large dispensing practices in Cambridgeshire, receiving repeat prescription for timolol [United Kingdom]</td>
<td>Not specified 1) Of the 55 subjects for whom dispensing information was available, 51% did not have sufficient timolol to medicate as prescribed. The average shortfall was 85 days over 12 months. 2) 24% of patients admitted to omitting treatment either frequently or occasionally</td>
</tr>
<tr>
<td>Schwartz&lt;sup&gt;38&lt;/sup&gt;</td>
<td>Retrospective observational using Rx claims. Cohorts: latanoprost, timolol</td>
<td>A) Time to DC (90-day [1 bottle] and 180-day gap [2 bottles]) B) Time to DC or Tx change</td>
<td>1474 patients who were 20+ years, were glaucoma suspects, were new to Tx, in commercial and Medicare-risk plans in HMO or PPO [US]</td>
<td>1997–2002 Mean (range) of persistence of cohorts at 1 year: A) 31% (25%–39%) B) 23% (18%–30%)</td>
</tr>
<tr>
<td>Shaya&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Retrospective observational using Rx claims. Cohorts: brimonidine, latanoprost, timolol</td>
<td>Time to DC (120-day gap)</td>
<td>2283 patients, 20–64 years, enrolled in Care First BCBS managed care plans, new to glaucoma Tx [Maryland in US]</td>
<td>1999–2001 Mean (range) of persistence of cohorts at 1 year: 18% (11%–25%)</td>
</tr>
<tr>
<td>Spooner&lt;sup&gt;40&lt;/sup&gt;</td>
<td>Retrospective observational using Rx claims. Cohorts: betaxolol, brimonidine, latanoprost, timolol</td>
<td>A) Time to DC (120-day [2.5, 5, 10 mL] and 180-day gap [15 mL]) B) Time to DC or Tx change</td>
<td>1006 patients, 20 to 64 years, enrolled in Blue Cross of California, new to glaucoma Tx [California in US]</td>
<td>1998–1999 Mean (range) of persistence of cohorts at 1 year: A) 29% (21%–44%) B) 22% (15%–36%)</td>
</tr>
</tbody>
</table>

(Continued)
Table S2 (Continued)

<table>
<thead>
<tr>
<th>Study group</th>
<th>Design/cohorts</th>
<th>Endpoint</th>
<th>Patient/setting</th>
<th>Study year</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stryker59</td>
<td>Prospective observational using</td>
<td>A) Non-adherent with taking medication:</td>
<td>80 participants, 18–80 years, white or African-American, with OAG, glaucoma suspect or OHT, at 2 VA hospital-based eye clinics, had Tx since at least the past year [Southeast US]</td>
<td>2007</td>
<td>60% of the sample was classified as non-adherent (were non-adherent with taking medication, had refill non-adherence, or missed any visit appointment in past year). Of these, A) 67% were non-adherent with taking medication as prescribed B) 50% had refill non-adherence C) 29% were non-adherent for appointment keeping</td>
</tr>
<tr>
<td></td>
<td>1) prescription records</td>
<td>had both a physician note about non-adherence and self-report of missing at least 1 dose of medication in a week</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2) chart review</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3) patient interview.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cohorts: none</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traverso51</td>
<td>Retrospective observational using Rx claims. Cohorts: Patients with OHT, POAG</td>
<td>A) Coverage: percentage of days during which a patient was in possession of any glaucoma medication during 1st year</td>
<td>57,803 patients, 18+ years in multiple managed care database, with OHT or POAG diagnosis, following Rx for IOP-lowering medication within 12 months, and 12+ months follow-up [US]</td>
<td>1998–2005</td>
<td>A) Mean medication coverage was significantly higher for the POAG cohort 50% (SD = 0.26) than for the OHT cohort 40% (0.25) B) The 75th percentile of coverage for all medicated patients (OHT and POAG) was 71.3%</td>
</tr>
<tr>
<td>Wilensky50</td>
<td>Retrospective observational using Rx claims. Cohorts: bimatoprost, latanoprost, travoprost</td>
<td>A) Days persistent was measured from the date of the first claim through the end of the adjusted days supply of the last claim during the 12-month observation period</td>
<td>2424 patients in indemnity and PPO health plans, new to IOP-lowering medication, who continued for at least 3 months of therapy and took only a single Tx during the observation period [US]</td>
<td>2001–2002</td>
<td>A) 69.3% were persistent for 1 year or longer B) Mean adherence (had medication available for use) was 76.3% (278 days) during the 1st year</td>
</tr>
<tr>
<td>Yeaw1</td>
<td>Retrospective observational using Rx claims. Cohorts: prostaglandin analogs, statins, bisphosphonates, oral antidiabetics, angiotensin II receptor blockers (ARBs), overactive bladder (OAB) medications</td>
<td>A) Persistence (on any prostaglandin rather than on specific agents) was defined as time to DC (30-day, 60-day, and 90-day gaps)</td>
<td>3310 patients (prostaglandin cohort) in multiple managed care database, with glaucoma diagnosis, and new to prostaglandinTx [US]</td>
<td>2005–2007</td>
<td>A) Persistence at 1 year: 32% (60-day gap) B) Mean adherence (SD) at 1 year was 37% (26%)</td>
</tr>
<tr>
<td>Yousuf50</td>
<td>Retrospective observational using inpatient prescriptions</td>
<td>Adherence defined as ratio of doses administered in the hospital to doses expected (based upon the dosing regimen identified from the outpatient prescription noted on admission)</td>
<td>184 patients discharged with a diagnosis of glaucoma at 2 community hospitals and receiving ocular hypotensive therapy [Pennsylvania in US]</td>
<td>2006–2009</td>
<td>In the hospital setting mean adherence rate was 67.3% (SD = 29.4%). 51.6% of patients received &lt; 75% of expected doses while 20.6% received &lt; 50% of doses. Knowing (P &lt; 0.01) and</td>
</tr>
</tbody>
</table>
Compliance and persistence in glaucoma prescribing (P < 0.01) the complete outpatient regimen upon admission was associated with adherence. Neither class of topical glaucoma medication nor the number of medications was significantly associated with adherence.

**Zhou**
- Retrospective observation using Rx records and electronic medical record. Cohorts: beta blockers, prostaglandins
- A) Time to failure [change in Tx or surgery]
- B) Time to DC (2 × days supply duration or 60 days) or failure
- I) Descriptive tree of multiple endpoints, including:
  - A) proportion persistent (60–day [2.5 mL bottle], 90-day [5 mL bottle], and 120-day gap [≥5 mL]) during 1st year (includes monotherapy, add-on therapy)
  - B) Proportion persistent or restarting index therapy during 1st year
  - C) Proportion switching therapy during 1st year
  - D) Proportion discontinuing and no longer using any medication at end of year
  - 2) Any adherence-related comment entered in the chart was recorded as positive (eg, “Patient compliant with drops”) or negative (eg, “Patient not compliant with regimen”) [DC of index medication was considered a switch].
- 3) Reported starting then discontinuing a previously prescribed medication

**Zimmerman**
- GAPS
- 1) Retrospective observation using Rx claims
- 2) Phone interviews with ophthalmologists
- 3) Phone interviews with patients
- 4) Chart review. Compliance findings reported only for 1) above. Cohorts: bimatoprost, latanoprost, travoprost
- A) 2001 newly diagnosed OAG patients new to Tx in the GPRD database [United Kingdom]
- B) 1999–1999
- C) Mean (range) of persistence of cohorts at 1 year:
  - A) 72% (55%–86%)
  - B) 56% (37%–69%)
  - I) 6271 patients age 40+ years, with diagnosis of OAG and new to Tx and receiving monotherapy, with 12+ months follow-up, enrolled in health network [US]
- 1) Mean (range) of cohorts at 1 year:
  - A) 10% (5%-11%)
  - B) 65% (58%-68%)
  - C) 16% (14%-21%)
  - D) 19% (18%-21%)
- 2) Any adherence-related comment entered in the chart was recorded as positive (eg, “Patient compliant with drops”) or negative (eg, “Patient not compliant with regimen”) [DC of index medication was considered a switch].
- 3) Among the 37% of patients who reported starting and then discontinuing a previously prescribed medication, adverse effects were by far the most common (44%) reason reported for stopping the medication, followed by perceived lack of efficacy (19%).

Note: *Engage Digitizer 4.1 (www.digitizer.sourceforge.net) was used to translate the plot line for each cohort to a spreadsheet of persistence values.*

**Abbreviations:** BCBS, Blue Cross Blue Shield; DC, discontinuation; DIN-LINK, a primary care/family practice electronic medical record database in the United Kingdom; GAPS, Glaucoma Adherence and Persistency Study; GPRD, General Practice Research Database (a primary care/family practice electronic medical record database in the United Kingdom); HMO, health maintenance organization; iOP, intraocular pressure; MPR, medication possession ratio; OAG, open-angle glaucoma; OHT, ocular hypertension; POAG, primary open-angle glaucoma; PPO, preferred provider organization; RAMQ, Régie de l’assurance maladie du Québec; Rx, prescription; SD, standard deviation; Tx, therapy; VA, Veterans Affairs.
### Table S3 Measurement of persistence – medical chart review studies

<table>
<thead>
<tr>
<th>Study group</th>
<th>Design/cohorts</th>
<th>Endpoint</th>
<th>Patient/setting</th>
<th>Study year</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arias61</td>
<td>Retrospective observational using chart review. Cohorts: latanoprost, bimatoprost, travoprost, timolol</td>
<td>Time to Tx DC or change, or referral to surgery</td>
<td>191 patients, 18+ years, seen at hospital clinic with glaucoma or OHT, initiated with monotherapy, not required to be new to Tx [Madrid, Spain]</td>
<td>2003–2004</td>
<td>Mean (range) of persistence of cohorts at 1 year: 78% (50%–91%)</td>
</tr>
<tr>
<td>Day62</td>
<td>Retrospective multicenter observation using chart review. Cohorts: latanoprost, bimatoprost, beta blockers</td>
<td>Time to Tx change</td>
<td>1182 patients, 18+ years, diagnosis of POAG or OHT at ophthalmologist practices, may/may not be new to Tx [South Carolina, Georgia, Florida in US]</td>
<td>1996–2002</td>
<td>Mean (range) of persistence of cohorts at 1 year: 64% (57%–71%)</td>
</tr>
<tr>
<td>Diestelhorst63</td>
<td>Retrospective multicenter observation using chart review. Cohorts: beta blockers, latanoprost</td>
<td>Time to Tx DC</td>
<td>260 patients, 18+ years, with diagnosis of POAG, were treatment-naive, at ophthalmology practices and clinics [Germany, Italy, Spain, United Kingdom]</td>
<td>1996–2000</td>
<td>Mean (range) of persistence of cohorts at 1 year: 62% (46%–83%)</td>
</tr>
<tr>
<td>Hahn11</td>
<td>GAPS. 1) Retrospective observation using Rx claims, 2) Phone interviews with ophthalmologists, 3) Phone interviews with patients, 4) Chart review. [Persistence findings reported for 4) above] Cohorts: bimatoprost, latanoprost, travoprost</td>
<td>4) Time to DC or Tx change</td>
<td>223 patients from database cited in Zimmerman et al who also had chart review data, age 40+ years, with diagnosis of OAG and new to Tx and receiving monotherapy, with 12+ months follow-up, enrolled in health network [US]</td>
<td>1999–2005</td>
<td>Mean (range) of persistence of cohorts at 1 year: 63% (58%–71%)</td>
</tr>
<tr>
<td>Kashiwagi65</td>
<td>Retrospective observation using patient registry. Cohorts: latanoprost, prostaglandins, beta-blockers, carbonic anhydrase inhibitors, pilocarpine, epinephrine, bunazosin</td>
<td>Persistence for ophthalmic solutions prescribed in 2001 [not further described]</td>
<td>1955 glaucoma patients in clinical registry at university glaucoma clinic who were newly prescribed an antiglaucoma agent for 1+ months [Japan]</td>
<td>2000–2008</td>
<td>Mean (range) of persistence of cohorts at 1 year: not reported</td>
</tr>
<tr>
<td>Tingey64</td>
<td>Retrospective observational using chart review. Cohorts: Phase I – patients starting first-line glaucoma treatment, Phase 2 – patients in whom first-line monotherapy with a β-blocker had failed and a second-line agent was being added or substituted (Phase 2)</td>
<td>Time persistent defined as the proportion of patients remaining on that therapy each month after initiation. Change in therapy defined as the addition of a medication, a switch to an alternative medication or a referral to surgery</td>
<td>115 patients, 18+ years with who had begun therapy for newly diagnosed POAG or OHT, at private ophthalmology practices and outpatient clinic [Alberta in Canada]</td>
<td>1998–1999</td>
<td>Mean (range) of persistence of cohorts at 1 year: Phase I was 69% (63%–87%); Phase 2 was 65% (64%–69%)</td>
</tr>
</tbody>
</table>

**Note:** *Engage Digitizer 4.1 (www.digitizer.sourceforge.net) was used to translate the plot line for each cohort to a spreadsheet of persistence values.*

**Abbreviations:** DC, discontinuation; GAPS, Glaucoma Adherence and Persistency Study; MPR, Medication Possession Ratio; OAG, open-angle glaucoma; OHT, ocular hypertension; POAG, primary open-angle; Rx, prescription; Tx, therapy.
Compliance and persistence in glaucoma